Summary New therapeutic strategies are now being developed against adenocarcinoma associated with erbB-2 amplification, particularly by inhibiting p185erbB-2 expression. Antisense oligodeoxynucleotides seem promising for this purpose as long as they are efficiently protected against degradation and targeted into the cells. We present antisense oligonucleotide carriers, the supramolecular biovectors (SMBVs), for which we have already demonstrated the ability to improve both cellular uptake and protection of oligodeoxynucleotide. The present work demonstrates that SMBVs elicit a specific and non-toxic action of antisense compounds in a cell model, irrespective of their sensitivity to nucleases. This is a major point, considering the specificity problems associated with the use of nuclease-resistant phosphorothioate oligodeoxynucleotide. SMBVs improve antisense efficiency of oligodeoxynucleotide designed against p185erB-2, with a complete growth arrest of SK-Br-3, human adenocarcinoma mammary cells that overexpress p18ertB-2 and no effect on MCF-7 cells that normally express p1 85ertB-2. The comparison of SMBVs with DOTAP reveals the statistically higher efficiency of SMBVs, which allows the antisense inhibition of p1 85erbB-2 expression in 65-75% of SK-Br-3 cells (P < 0.05). The efficiency and controlled synthesis of SMBVs underline their potentialities as oligodeoxynucleotide carriers for in vivo experiments.
tyrosine kinase growth factor receptor, the protein p1 85erbB-2 (King et al, 1985) . Overexpression of Pl85erbB-2 is strongly correlated with the development of a number of human adenocarcinomas and results from gene amplification and/or transcriptional deregulation. This overexpression is associated with around 30% of breast and ovarian tumours (Dougall et al, 1994) , in which it has been correlated with short time to relapse and poor patient survival (Slamon et al, 1987; Yu et al, 1994) .
New therapeutic strategies of the various adenocarcinomas associated with erbB-2 amplification have been developed, which inhibit either P185erbB-2 function or P185erbB-2 expression. The former case is based on the use of monoclonal antibodies, immunotoxins and tyrosine kinase inhibitors (Stancovski et al, 1991; Bacus et al, 1992; Beerli et al, 1995; King et al, 1996) . Monoclonal antibodies specific for the extracellular domain of P185erbB-2 can inhibit erbB-2-dependent tumour growth but can also act as receptor agonists (Stancovski et al, 1991) . Moreover, such treatments are equally efficient for both cell types without discriminating between cells that express elevated amounts of P185erbB-2 and those that show low levels (Bacus et al, 1992) . A challenging approach consists of the use of antisense oligodeoxynucleotides (ODNs) , in the inhibition of P185erbB-2 expression, designed to hybridize to erbB-2 mRNA. Such antisense ODNs inhibit P1 85erbB-2 expression in vitro and, in turn, cell proliferation (Bertram et al, 1994; Brysch et al, 1994; Colomer et al, 1994; Vaughn et al, 1995; Wiechen and Dietel, 1995) .
A comparative study outlined the superiority of the inhibition by antisense ODN: whereas the inhibitory activity of a monoclonal antibody or a tyrosine kinase inhibitor only lasted a few hours, antisense ODN inhibition could be detected over several days (Wiechen and Dietel, 1995) . Nevertheless, the use of ODNs is still limited by two major drawbacks: their poor diffusion through plasma membranes and their rapid degradation by nucleases (Helene and Toulme, 1990) . The antisense inhibition of PI85ebB-2 in SK-Br-3 cells, a human mammary adenocarcinoma cell model overexpressing the transmembrane receptor, has thus necessitated the use of either native phosphodiester ODNs at a very high concentration (Colomer et al, 1994) or nuclease-resistant phosphorothioate ODNs, carried by commercialized cationic lipids or not (Bertram et al, 1994; Brysch et al, 1994; Vaughn et al, 1995) . Because the evidence is becoming stronger for the non-sequencespecific effects of phosphorothioate ODN (Stein and Cheng, 1993; Gura, 1995; Stein, 1995) , the development of ODN carriers would seem necessary to improve both the transport and the stability of native ODNs, while preserving their target specificity. Synthetic commercialized cationic lipids, such as DOTMA or DOTAP (Capaccioli et al, 1993; Dean and Mckay, 1994) , or synthetic carriers such as nanoparticles (Schwab et al, 1994) are widely used because of their efficiency in enhancing antisense ODN uptake into cells and decreasing their degradation. These ODN carriers are promising for in vitro experiments and local administration, but their instability and the cellular toxicity of these complexes limit their use for in vivo systemic administration (Lewis et al, 1996) .
The SupraMolecular BioVectors (SMBVs) are new potential antisense ODN carriers. These are multilayered particles composed of an internal ionic polysaccharide core surrounded by a lipid layer (Peyrot et al, 1994; Samain et al, 1994) . By modulating the charge of the internal core, various molecules, such as interleukin 2 (Castignolles et al, 1994) or gentamycin and doxorubicin (De Miguel et al, 1995) , have been efficiently incorporated into SMBVs. The limitation of their size to around 30 nm diameter means that a high diffusibility of the carriers, not only into tissues and organs but also within cells, can be predicted. SMBVs characterized by cationic cores have been developed and proved to incorporate anionic ODNs efficiently and stably (Berton et al, 1997) . We have already reported that SMBVs bring about a significant increase in cellular ODN uptake and protection (Berton et al, 1997) .
The aim of the present work was to evaluate the ability of SMBVs to improve the antisense effect of both phosphorothioate and phosphodiester ODNs, designed to inhibit erbB-2 mRNA translation, in two cell models overexpressing P185erbB-2 or not. The antisense effect was proved by analysis of the protein expression and the proliferation, in comparison with DOTAP, a wellknown, commercialized antisense ODN carrier.
MATERIAL AND METHODS Antisense oligodeoxynucleotides
We used 15-mer oligodeoxynucleotides (ODNs) with a sequence complementary to the AUG initiation codon of erbB-2 mRNA (5'CTC CAT GGT GCT CAC-3') and the scrambled sequence (5'-CGC CTT ATC CGT AGC-3'). Incorporation of ODNs into SMBVs As described previously (Berton et al, 1997) , ODN solution in water was slowly added to SMBV suspension (I mg of polysaccharide core ml-'; Biovector Therapeutics, France) and incubated at 45°C with magnetic stirring for 5 h. The incorporation yield was 100% with an initial incorporation ratio of 10% (w/w). optimal to obtain maximum cumulative ODN uptake (Berton et al, 1997) . According to the supplier's recommendations, a minimal 3-h incubation of DOTAP-ODN complex with cells allows optimal ODN uptake, and lipofection of SK-Br-3 cells has been shown to be optimal after a 4-h incubation with ODN-cationic lipid complex (Vaughn et al, 1995) .
In agreement with the long half-life time of P185erbB-2 (> 12 h; Vaughn et al, 1995), we determined that 72 h was the optimal lag time for the analysis of P185erbB-2 downregulation (data not shown). -We checked that, at the SMBV concentration used (180 jig ml-1), more than 70% of SK-Br-3 cells were viable [metabolic activity by MTT test as described previously (Berton et al, 1997) ] after 72 h, thus indicating the low toxicity of the carrier.
p1 85erbB-2 expression analysis
This analysis was performed as described previously (Vaughn et al, 1995) . Briefly, 7 x 104 cells were seeded per well in 24-well plates and treated, as described above, in a final volume of 300 pl.
After 72 h, the culture medium was removed, and the cells were collected by trypsinization, washed three times with ice-cold wash buffer (0.5% FBS and 0.1% sodium azide in PBS), then resuspended in 100 jil of an ice-cold phosphate-buffered saline (PBS) solution containing 0.1% bovine serum albumin (BSA), 0.1% sodium azide and 0.25 jig ml-1 erbB-2 mouse monoclonal antibody (0P39; Oncogene Science, France). Cells were incubated at 40C for 1 h, washed three times in wash buffer and resuspended in 50 jil of an ice-cold PBS solution containing 0.1I% BSA, 0.1I% sodium azide and 10 jig ml-' phycoerythrin-labelled goat antimouse conjugate (Molecular Probes, France Figure IC) . A dramatic change in the dot-plot is observed for the SK-Br-3 cells treated with antisense phosphorothioate ODNs incorporated into SMBVs ( Figure ID) . Some 65% of cells are shifted to a lower pl85erbB-2 expression level. The treatment of MCF-7 cells by antisense phosphorothioate ODNs incorporated into SMBVs does not lead to such impressive changes as in SK-Br-3 cells ( Figure 1E) . A lower threshold value was set horizontally on the dot-plot, in such a way that 94% of control cells had a higher pl85erbB-2 expression level. Only a few cells exhibited a lower fluorescence intensity than this second threshold value (10 arbitrary units).
The results, expressed as percentages of cells exhibiting p1 85erbB-2 at lower or at higher levels than the threshold values, are summarized in Figure 2 . Results obtained with SK-Br-3 cells (Figure 2A) Only 13% of the MCF-7 cells ( Figure 2B ) display a lower level of pl85erbB-2 expression when treated with antisense ODNS incorporated into SMBVs. This result is statistically different from the 6% obtained under control conditions (P < 0.05), but use of the antisense ODN-DOTAP complex leads to similar inhibition (16.5%).
The incubation of both SK-Br-3 and MCF-7 cells with free phosphorothioate ODNs does not induce any antisense effect at the protein level (Figure 2A and B) .
Cell proliferation inhibition
The SK-Br-3 cell growth kinetics demonstrate that antisense phosphorothioate ODNs, whether incorporated into SMBVs ( Figure 3A) or associated with DOTAP ( Figure 3B ), induce a complete inhibition of cell growth during the 120 h after treatment. Nevertheless, it should be noted that DOTAP (free or associated with scrambled ODN) totally blocks cell growth for 72 h, whereas little alteration in cell growth is obtained with SMBVs alone. The incubation of cells with free phosphorothioate ODNs does not induce any antisense effect, tested in terms of cell proliferation (data not shown).
In the case of MCF-7 cells ( Figure 3C and D) , antisense phosphorothioate ODNs, whether incorporated into SMBVs ( Figure 3C ) or associated with DOTAP ( Figure 3D ), do not induce the complete arrest of cell growth observed in SK-Br-3 cells. Slight toxicity is observed with both carriers but is not distinguishable from the growth inhibition caused by either antisense or scrambled ODNs.
Nuclease-sensitive phosphodiester ODNs
The comparison of SK-Br-3 cells treated with phosphodiester ( Figure 4 ) and phosphothioate ( Figure 2A ) ODNs reveals similar behaviour. The cells display a decreased level of p185erbB-2 after incubation with antisense phosphodiester ODNs incorporated into SMBVs (74%) or associated with DOTAP (45%). SMBVs thus clearly elicit a higher inhibition by antisense ODNs than DOTAP (P < 0.05). Control experiments using scrambled phosphodiester ODNs have demonstrated that the downregulation of pl85e6B-2 expression is the result of a specific action of antisense phosphodiester ODNs.
British Journal of Cancer (1998) 77(9) (Lewis et al, 1996) . The present work clearly demonstrates the ability of SMBVs, a non-toxic synthetic ODN carrier, to elicit the complete cell growth arrest of pl85erbB-2-overexpressing cells by antisense ODN. This blockage results from a dramatic inhibition of p1 85ebB-2 expression, which is significantly higher than that induced by ODN-DOTAP complexes. Moreover, this work underlines the fact that native phosphodiester ODNs, when associated with SMBVs, are as efficient as phosphorothioate ODNs in inhibiting pl85erbB-2 expression, thus circumventing the specificity problems associated with the latter. In a previous work, we showed that SMBVs significantly increase ODN uptake in the cell cytosolic fraction (Berton et al, 1997) , which should lead to an improved effect of phosphorothioate ODNs. As expected, a specific inhibition of pl85erbB-2 expression is observed in SK-Br-3 cells, whereas free ODNs have no effect. Moreover, a significantly higher percentage of cells shows an inhibition of plret,B-2 expression when the ODNs are carried by SMBVs (65%) rather than by DOTAP (40%). In both cases, a complete and antisense-specific growth arrest of SK-Br-3 cells is obtained.
It is noteworthy that SMBVs alone only slow down SK-Br-3 cell growth under these conditions (more than 70% of SK-Br-3 cells viable after 72 h), whereas DOTAP induces a complete and non-specific growth arrest during the first 72 h after the treatment. This phenomenom can be caused by toxicity, detachment or other mechanisms that we have not identified. It is only after 96 h that a specific antisense inhibition of cell growth can be distinguished from the intrinsic toxicity of the DOTAP. In contrast, neither SMBVs nor DOTAP are toxic to MCF-7 cells under the same treatment conditions. A sensitivity to carriers that is dependent on the cell type is thus apparent. The non-sequence-specific effects of phosphorothioate antisense ODNs strongly restrict their possibilities for clinical trials (Stein and Cheng, 1993; Gura, 1995; Stein, 1995) . In our previous work, it was demonstrated that incorporation into SMBVs increases the half-life time of phosphodiester ODNs 11-fold in cell growth medium (Berton et al, 1997) . Furthermore, a high proportion of ODNs present in the cell cytosol was shown to remain intact if incorporated into SMBVs, whereas free ODNs were completely degraded (Berton et al, 1997) . Indeed, other studies estimated that free DNA ODN half-life time is around 30 min in cytosol (Fisher et al, 1993) . Comparison of the ability of SMBVs to improve the antisense effect of phosphodiester and phosphorothioate ODNs was thus a key point. We confirm here that native and nuclease-resistant ODNs have a similar antisense effect with regard to pl85e6B-2 expression when incorporated into SMBVs. This result demonstrates that the incorporation of ODNs into SMBVs allows their long-term protection, suggesting that SMBVs do not degrade immediately after entry into cells. Again, a specific inhibition of pl85erbB-2 expression is observed in a significantly higher percentage of SK-Br-3 cells, using phosphodiester ODNs carried by SMBVs (74%) than with phosphodiester ODNs carried by DOTAP (45%). This demonstrates that SMBVs are efficient native ODN carriers at the cellular level as regards improved ODN uptake and protection.
A differential antisense effect of ODNs in cells that overexpress or normally express a protein is of major interest in obtaining selective growth inhibition of tumoral cells characterized by a gene amplification (e.g. myc and erbB-2). It has already been shown that the preferential accumulation and retention of antisense ODNs in cells correlate with the number of target mRNA copies (Dewanjee et al, 1994; Urbain et al, 1995) . We have shown that p185erbB-2 overexpression in SK-Br-3 cells (950 arbitrary units) is decreased 19-fold by ODNs incorporated into SMBVs to the normal expression level observed in control MCF-7 cells (50 arbitrary units). Besides, only 13% of MCF-7 cells have the pl85erbB-2 expression lowered 12.5-fold to close to the background level of the MDA-MB-468 cells (4 arbitrary units), known not to express pl85erIB-2 (Kraus et al, 1987) . As it has been proved that SMBVs efficiently enter MCF-7 cells (Berton et al, 1997) , these results suggest that ODNs incorporated into SMBVs have access or hybridize to target mRNA more efficiently in pl85erbB-2-overexpressing cells than in those normally expressing p185erbB-2. The abundance and/or accessibility of mRNA in the cytoplasm of cells overexpressing a protein would be the preferential target for antisense ODNs incorporated into SMBVs (Xing et al, 1993; Dewanjee et al, 1994; Urbain et al, 1995) . This hypothesis has to be demonstrated now on various cell lines in order to eliminate the possibility of antisense and lipid variability effects among different cell lines. Indeed, a difference in degradation or elimination of ODNs among MCF-7 and SK-Br-3 cells may exist.
In this report, the use of SMBVs as ODN carriers is shown to elicit a specific, non-toxic action of antisense ODNs, irrespective of their nuclease sensitivity. The synthesis of SMBVs can be perfectly controlled and modulated (lipid composition, particle charge and size) to allow optimal stability of the ODN-SMBV complexes in physiological conditions and possible cell targeting. SMBVs are thus revealed to be promising antisense ODN carriers, the development of new phosphodiester ODN carriers for clinical purposes being a crucial issue (Lewis et al, 1996) .
